Patienter som har oplevet mindst 1 attak i det forudgående år, mens de var i behandling, og som har mindst 9 T2- hyperintense læsioner påvist ved kraniel MR- scanning eller mindst 1 gadolinium- forstærket læsion.
Patients should have had at least 1 relapse in the previous year while on therapy, and have at least 9 T2-hyperintense lesions in cranial MRI or at least 1 Gadolinium-enhancing lesion.